CANDIDATE FDA-APPROVED DRUGS THAT MAY MIMIC HOXA CLUSTER DELETION IN MLL-AF9 LEUKEMIA.
EHA Learning Center, Laura Kettyle, 214634
MUTATIONAL LANDSCAPE OF RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA
EHA Learning Center, Valentina Alfonso, 214635
IMPACT OF NPM1 MRD STATUS AFTER TWO CYCLES OF INTENSIVE CHEMOTHERAPY TO INFORM TYPE OF POST-REMISSION THERAPY: A STUDY OF THE AML STUDY GROUP (AMLSG)
EHA Learning Center, Silke Kapp-Schwoerer, 214651
TRANSLATOME ANALYSIS REVEALS ALTERED SERINE METABOLISM IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Kim Kampen, 215234
TITLE: PROGNOSTIC IMPACT OF THE BCR/ABL1-LIKE SIGNATURE IN ADULT B-LINEAGE ALL. FIRST ANALYSIS OF THE GIMEMA LAL1913 PROTOCOL
EHA Learning Center, Sabina Chiaretti, 215235
FIRST RESULTS OF NEW GIMEMA TRIAL LAL1913 FOR ADULT PATIENTS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH- ALL)
EHA Learning Center, Renato Bassan, 215251
LOW MIR-151 AND MIR-451 LEVELS IN BONE MARROW AT DIAGNOSIS IS CONFIRMED AS A PROGNOSTIC FACTOR FOR RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE AIEOP 2000 CLINICAL TRIAL
EHA Learning Center, Jennifer Yarden, 215252
IDENTIFICATION OF CALM/AF10 (PICALM/MLLT10) COOPERATING MUTATIONS IN A ZEBRAFISH LEUKAEMIA MODEL
EHA Learning Center, Omid Delfi, 215268
FLT3-ITD ANALYSIS ON RNA CONFERS ENHANCED SENSITIVITY AND ALLOWS EARLIER RELAPSE PREDICTION
EHA Learning Center, Elisabeth Oppliger Leibundgut, 215269
TOWARDS IMPROVING OF SURVIVAL IN AML BY REPURPOSING EXISTING DRUGS AS NOVEL SAMHD1 INHIBITORS
EHA Learning Center, Nikolaos Tsesmetzis, 215284
GENOMIC-DRIVEN AND FUNCTIONAL ALTERATIONS IN ENERGY, AMINO ACID AND LIPID METABOLISM IN ACUTE MYELOID LEUKEMIA BLASTS AND STEM PROGENITOR CELLS
EHA Learning Center, Giorgia Simonetti, 215285
P53(D281G) MUTATION CAUSES CYTARABINE RESISTANCE VIA PROMOTING WARBURG EFFECT IN ACUTE MYELOID LEUKEMIA CELLS
EHA Learning Center, Kit Man Ng, 215301
EVALUATION OF THE DRUG INTERACTION POTENTIAL OF PRACINOSTAT, A NOVEL HISTONE DEACETYLASE (HDAC) INHIBITOR, WITH CYP1A2 INDUCER CIGARETTE SMOKING AND CIPROFLOXACIN, A CYP1A2 INHIBITOR
EHA Learning Center, Alberto Bernareggi, 215302
THE CXCR4 INHIBITOR BL-8040 IN COMBINATION WITH CYTARABINE RESULTS IN A SIGNIFICANTLY EXTENDED OVERALL SURVIVAL OF RELAPSED/REFRACTORY AML PATIENTS
EHA Learning Center, Gautam Borthakur, 215317
CELL-FREE DNA MONITORING OF MINIMAL RESIDUAL DISEASE IN AML USING A TARGETED NGS GENE PANEL
EHA Learning Center, Zhiyi Xie, 215318
BLAST TRANSFORMATION IN MYELODYSPLASTIC AND MYELOPROLIFERATIVE NEOPLASMS - SIMILARITIES AND DIFFERENCES - A REVIEW OF 100 CASES
EHA Learning Center, Milan Jagurinoski, 215332
QUALITY OF LIFE IN ACUTE LEUKEMIA PATIENTS WITH COMORBID ISCHEMIC HEART DISEASE
EHA Learning Center, Tetiana Lymanets, 215333
BIOMARKER ANALYSIS OF TISAGENLECLEUCEL PRE-INFUSION BIOPSIES OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Learning Center, Ulrich Jäger, 215334
A NOVEL IMMUNOHISTOCHEMICAL PROGNOSTIC SCORE BASED ON MYC, BCL2 AND BCL6 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RETROSPECTIVE ANALYSIS OF DE NOVO DLBCL TREATED WITH RITUXIMAB-CHOP
EHA Learning Center, Mattia Novo, 215348
ASSESSMENT OF BONE MARROW INFILTRATION AND MINIMAL RESIDUAL DISEASE BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, M Baile, 215349
ON THE APPLICABILITY OF RHOA GLY17VAL POINT MUTATION TESTING FOR A DIFFERENTIAL DIAGNOSIS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
EHA Learning Center, Yulia Sidorova, 215350
BEVACIZUMAB SIGNIFICANTLY IMPROVES SEVERE EPISTAXIS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA
EHA Learning Center, Silva ZUPANCIC SALEK, 215364
AN AUDIT OF THE USE OF PROTHROMBIN COMPLEX CONCENTRATION
EHA Learning Center, Samantha Bonney, 215365
HAEMOSTATIC ABNORMALITIES OR DEFECTS IN GREEK PATIENTS WITH GAUCHER DISEASE
EHA Learning Center, Veroniki Komninaka, 215366
RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN CONGENITAL BONE MARROW FAILURE SYNDROMES: SINGLE CENTER EXPERIENCE WITH FOCUS ON TCR ΑΒ+/CD19+ DEPLETION
EHA Learning Center, Zhanna Shekhovtsova, 215380
REACTIVATION OF HEPATITIS B VIRUS INFECTION IN APLASTIC ANEMIA PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY
EHA Learning Center, Guangsheng He, 215381
ADULT PATIENTS WITH ACQUIRED PURE RED CELL APLASIA: COMBINATION OF CYCLOSPORINE A AND CORTICOSTEROIDS PRODUCE BETTER CR
EHA Learning Center, Guangsheng He, 215382
ENCYCLOPEDIA OF CLL SUBSETS: AN ONLINE KNOWLEDGEBASE FOR SUBSETS OF CLL CASES WITH STEREOTYPED B CELL RECEPTORS
EHA Learning Center, Tomas Reigl, 215397
ANALYSIS OF LOCUS-SPECIFIC LINE-1 AND ALU ELEMENT DNA METHYLATION REVEALS NOVEL EARLY EPIGENETIC CHANGES IN CHRONIC LYMPHOCYTIC LEUKAEMIA
EHA Learning Center, Timothy Barrow, 215398
ILT3/DELTEX-1/SHIP-1 AS A NOVEL INHIBITORY AXIS CONTROLLING B CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Anna Kabanova, 215399
SURVIVAL CONTINUES TO INCREASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS AMONG 19,131 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 1989 AND 2015
EHA Learning Center, Lina van der Straten, 215413
PROGNOSTICATION AND FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: A CONTEMPORARY, NATIONWIDE, POPULATION-BASED ANALYSIS AMONG 1,677 PATIENTS DIAGNOSED IN THE NETHERLANDS
EHA Learning Center, Lina van der Straten, 215414
“IMMUNO-FLOW-FISH”: HIGH THROUGHPUT FLUORESCENCE IN SITU HYBRIDISATION OF PHENOTYPED CHRONIC LYMPHOCYTIC LEUKAEMIA BY IMAGING FLOW CYTOMETRY FOR CLINICAL APPLICATION
EHA Learning Center, Wendy Erber, 215415
WT1 ANALYSIS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
EHA Learning Center, Sabrina COLUZZI, 215429
DIGITAL DROPLET PCR MAY BETTER IDENTIFY CANDIDATES FOR TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA REGARDLESS OF MEDIAN TREATMENT DURATION
EHA Learning Center, Gioia colafigli, 215430
FREQUENCY OF TYPICAL AND ATYPICAL FUSION TRANSCRIPTS IN PATIENTS WITH BCR-ABL1-POSITIVE LEUKEMIAS – A SINGLE INSTITUTION STUDY
EHA Learning Center, Gueorgui Balatzenko, 215431
THE OCCURRENCE AND SURVIVAL OF COLD AGGLUTININ DISEASE IN DENMARK
EHA Learning Center, Sigbjørn Berentsen, 215445
DENSITY, HETEROGENEITY AND DEFORMABILITY OF RED CELLS AS MARKERS OF CLINICAL SEVERITY IN HEREDITARY SPHEROCYTOSIS
EHA Learning Center, Richard van Wijk, 215446
LONG-TERM TREATMENT RESPONSE BASED ON SEVERITY OF GAUCHER DISEASE TYPE 1 AT BASELINE IN TREATMENT-NAÏVE ADULT PATIENTS AFTER 8 YEARS OF TREATMENT WITH ORAL ELIGLUSTAT
EHA Learning Center, Elena Lukina, 215448
CONSIDERATIONS FOR TISAGENLECLEUCEL DOSING RATIONALE
EHA Learning Center, Rakesh Awasthi, 215462
MTL-CEBPA, A SMALL ACTIVATING RNA FOR INTRAVENOUS ADMINISTRATION TO ENHANCE C/EBPΑ EXPRESSION IN PATIENTS WITH LIVER CANCER SHOWS POTENTIAL USE IN NEUTROPENIA
EHA Learning Center, Choon Tan, 215463
SIGNIFICANT ARI-0001 (A3B1:CD8:4-1BB:CD3Z CAR19) CELL EXPANSION IN A PATIENT WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PRE-LYMPHOAPHERESIS IBRUTINIB ADMINISTRATION.
EHA Learning Center, Valentín Ortiz-Maldonado Gibson, 215464
LYMPHOPENIA AND RISK OF INFECTIONS AND INFECTION-RELATED DEATH IN DENMARK, 2003-2013: A PROSPECTIVE COHORT STUDY OF 98,344 INDIVIDUALS FROM THE GENERAL POPULATION
EHA Learning Center, Marie Warny, 215478
HEMATOPOIETIC EFFECTS OF A COMPOUND: SXN AGAINST MYELOSUPPRESSION
EHA Learning Center, Fuling Zhou, 215479
IMPACT OF SPLENECTOMY ON CD34+ BLOOD COUNT
EHA Learning Center, Irina Galtseva, 215480
CHARACTERIZATION OF MALT LYMPHOMA WITH T(11;18): LONG-TERM FOLLOW-UP
EHA Learning Center, Kosuke Toyoda, 215494
CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): DESCRIPTION OF MAIN DISEASE FEATURES, CLINICAL COURSE AND OUTCOME IN A SERIES OF 98 CASES.
EHA Learning Center, Christina Kalpadakis, 215495
OVERALL SURVIVAL OF MANTLE CELL LYMPHOMA (MCL) PATIENTS HAS BEEN SIGNIFICANTLY IMPROVED DURING THE TIME, MAINLY DUE TO THE RITUXIMAB MAINTENANCE IN ELDERLY POPULATION, REAL WORLD DATA.
EHA Learning Center, Marek Trneny, 215496
RISK OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF NOVEL THERAPIES: A RETROSPECTIVE SINGLE INSTITUTION EXPERIENCE
EHA Learning Center, Francesco Autore, 215511
THERAPEUTIC ADMINISTRATION OF IGM-ENRICHED IMMUNOGLOBULINS IMPROVES SURVIVAL IN HEMATOLOGICAL CANCER PATIENTS WITH SEVERE NEUTROPENIC SEPSIS
EHA Learning Center, Alessandra Forcina, 215512
TETANUS, DIPHTHERIA AND POLIO IMMUNITY AFTER CHEMOTHERAPY AND RITUXIMAB IN PATIENTS WITH LEUKEMIA AND LYMPHOMA
EHA Learning Center, Sigrun Einarsdottir, 215513
IRON DEFICIENCY ANAEMIA – ZINC PROTOPORPHYRIN, A SIMPLE, FAST, INEXPENSIVE DIAGNOSTIC METHOD
EHA Learning Center, João Gomes, 215528
STUDY OF A MEDICO-ECONOMIC ADVANTAGE IN USING NEW PARAMETERS OF CBC-DIFF-RETIC IN THE EARLY DETECTION OF IRON DEFICIENCY FOR DIALYSIS PATIENTS**
EHA Learning Center, Elena Sukhacheva, 215529
ACERULOPLASMINAEMIA - THE EXTREMELY RARE ALSO EXISTS
EHA Learning Center, João Gomes, 215530
CHARACTERIZATION AND DIFFERENTIAL EFFECTS OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Manja Wobus, 215544
MYELODISPLASTIC SYNDROMES: MECHANISMS INVOLVED IN THE TRANSFORMATION TO ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Francisca Hernández Mohedo, 215545
COMPLETE BLOOD COUNT- BASED SCORE FOR THE DIAGNOSIS AND PROGNOSIS OF MYELODYSPLASTIC SYNDROMES IN CYTOPENIC PATIENTS
EHA Learning Center, Marion Eveillard, 215546
PREDICTIVE FACTORS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN HIGH-RISK OLDER PATIENTS WITH MDS AND CMML UNDER HYPOMETHILATING AGENTS. LATIN-AMERICAN MDS GROUP - GLAM
EHA Learning Center, Marcelo Iastrebner, 215560
IRON SUPPORT ENHANCES ERYTHROPOIETIN EFFECTIVENESS IN REFRACTORY ANEMIA WITH HIGH RETICULOCYTE COUNT, TRANSFERRIN SATURATION BELOW 30% AND HIGH LEVEL OF ERYPTOSIS.
EHA Learning Center, GIULIO GIORDANO, 215561
SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT
EHA Learning Center, Carolina Lazzarino, 215563
ELOTUZUMAB PROMOTES SELF-ENGAGEMENT OF SLAMF7 BETWEEN NATURAL KILLER AND MULTIPLE MYELOMA CELLS TO ENHANCE CYTOTOXICITY
EHA Learning Center, Michael D. Robbins, 215577
CARFILZOMIB-INDUCED CARDIOTOXICITY: MOLECULAR MECHANISMS AND THE EMERGING ROLE OF METFORMIN AS A PROPHYLACTIC THERAPY
EHA Learning Center, Evangelos Terpos, 215578
JAGGED1/2 INHIBITION PROMOTES TUMOR CELLS RESPONSE TO BORTEZOMIB IN A ZEBRAFISH MODEL OF MULTIPLE MYELOMA
EHA Learning Center, Maria Teresa Palano, 215579
DOUBLET VS TRIPLET LENALIDOMIDE-CONTAINING REGIMENS FOLLOWED BY MAINTENANCE: SUBGROUP ANALYSIS BY FRAILTY STATUS AFTER A MEDIAN FOLLOW-UP OF 5 YEARS (EMN01 PHASE III STUDY)
EHA Learning Center, Sara Bringhen, 215593
POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN CASE OF SUBOPTIMAL RESPONSE TO POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: RESULTS OF THE GMMG-PERSPECTIVE TRIAL
EHA Learning Center, Katja C Weisel, 215594
SKY92 RISK STRATIFICATION AT RELAPSE PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR STANDARD-RISK MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Rowan Kuiper, 215595
OVERALL SURVIVAL OF PATIENTS POST-TRANSPLANT: STUDY RESULTS FROM TWO PHASE 3 TRIALS ASPIRE AND ENDEAVOR
EHA Learning Center, Hartmut Goldschmidt, 215609
DURABLE PROGRESSION-FREE SURVIVAL BENEFIT IN EARLY RESPONDERS TO ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF 4-YEAR DATA FROM ELOQUENT-2
EHA Learning Center, Christof Scheid, 215610
SERIAL SERUM FREE LIGHT CHAIN ASSAY CAN REDUCE THE NEED FOR 24-HOUR URINE PROTEIN ASSESSMENT FOR RESPONSE ASSESSMENT IN MULTIPLE MYELOMA
EHA Learning Center, Marcella Tschautscher, 215611
QUALITY OF HEMATOLOGIC RESPONSE BUT NOT DEPTH OF NT-PROBNP RESPONSE IMPROVES SURVIVAL OF PATIENTS WITH AL AMYLOIDOSIS WHO ACHIEVE CARDIAC RESPONSE
EHA Learning Center, Paolo Milani, 215625
SUSTAINED MRD NEGATIVITY AT 12 MONTHS POST-ASCT PREDICTS OUTCOMES FOR MYELOMA PATIENTS: A REAL WORLD STUDY.
EHA Learning Center, Michael Austin, 215626
MULTIPLE MYELOMA IN PATIENTS UNDER 40 YEARS OLD: A RETROSPECTIVE ANALYSIS FROM THE INTERGOUPE FRANCOPHONE DU MYELOME (IFM).
EHA Learning Center, Alexis Caulier, 215627
IMPACT OF MOLECULAR ANALYSIS ON PROGNOSTIC SCORES IN ESSENTIAL THROMBOCYTHEMIA: A SINGLE CENTER PROSPECTIVE COHORT EXPERIENCE
EHA Learning Center, Damien Luque Paz, 215641
THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Kira Behrens, 215642
MANAGEMENT AND OUTCOME OF 25 PREGNANCIES IN WOMEN WITH POLYCYTHAEMIA VERA
EHA Learning Center, Irene Bertozzi, 215657
PEGYLATED INTERFERON ALPHA-2B VERSUS ΑLPHA-2A FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: EFFICACY AND SAFETY PROFILE.
EHA Learning Center, Novella Pugliese, 215658
CORRELATIONS BETWEEN GENETIC AND CLINICAL CHARACTERISTICS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
EHA Learning Center, Liubov Polushkina, 215673
MUTATIONAL PROFILES OF CLASSIC MYELOPROLIFERATIVE NEOPLASMS IN TAIWANESE PATIENTS: FREQUENCY AND CLINICAL CORRELATION
EHA Learning Center, Huan-Chau Lin, 215674
IMMUNOPROFILING OF HIV-ASSOCIATED LYMPHADENOPATHY: HIGH-THROUGHPUT ANALYSIS OF THE T CELL RECEPTOR GENE REPERTOIRE SUPPORTS EPITOPE-SPECIFIC T CELL RESPONSES
EHA Learning Center, Evangelia Stalika, 215690
SUPERIORITY OF AVATROMBOPAG TO PLACEBO IN I REDUCING PLATELET TRANSFUSIONS IN PATIENTS WITH THROMBOCYTOPENIA AND CHRONIC LIVER DISEASE UNDERGOING SCHEDULED PROCEDURES- POOLED ANALYSIS OF 2 STUDIES
EHA Learning Center, Kavita Aggarwal, 215691
CHANGES IN PLATELET AGGREGATION DURING PREGNANCY AND THE IMMEDIATE POSTPARTUM PERIOD
EHA Learning Center, Brwa Hussein, 215707
CHANGING PROFILE OF PLATELET ACTIVITY AND TURNOVER INDICES DURING TREATMENT RESPONSE OF IMMUNE THROMBOCYTOPENIA: PREDICATIVE VALUE OF REPONSE BY GLYCOCALICIN AND SOLUBLE CD40 LIGAND
EHA Learning Center, Hung Chang, 215708
HOW PHYSICIANS' AND PATIENTS' CHARACTERISTICS AFFECT THE LENGTH OF PATIENTS' VISIT IN THE HEMATO-ONCOLOGICAL CLINIC.
EHA Learning Center, IRINA AMITAI, 215724
SYSTEMATIC REVIEWS OF ECONOMIC BURDEN AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML)
EHA Learning Center, Rachel Bosshard, 215725
EARLY RECOGNITION OF THE SICKLING PROCESS OF ERYTHROCYTES BY LABEL-FREE LIGHT MICROSCOPIC IMAGING IN PATIENTS WITH SICKLE CELL DISEASE
EHA Learning Center, Irene Lorand Metze, 215741
SICKLE CELL DISEASE SEVERITY MEASURE: DEVELOPMENT, TRANSLATION, AND PATIENT CULTURAL SENSITIVITY VALIDATION
EHA Learning Center, Kenneth Bridges, 215742
A PHASE I/II TRIAL OF INTRAVENOUS AZACITIDINE FOR ACUTE GVHD PROPHYLAXIS IN PATIENTS UNDERGOING MATCHED UNRELATED STEM CELL TRANSPLANTATION: INTERIM PHASE II RESULTS
EHA Learning Center, Mark Schroeder, 215757
BUSULFAN FLUDARABINE (BU-FLU) COMPARED TO THIOTEPA BUSULFAN FLUDARABINE (TBF) FOR ALLOGENEIC TRANSPLANTS IN ACUTE MYELOID LEUKEMIA (AML) OR REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB) IN REMISSION
EHA Learning Center, Andrea Bacigalupo, 215758
LOW INCIDENCE OF SYMPTOMATIC OSTEONECROSIS AFTER ALLOGENEIC HSCT IN CHILDREN WITH HIGH-RISK OR RELAPSED ALL – RESULTS OF THE ALL-SCT 2003 TRIAL
EHA Learning Center, Michaela Kuhlen, 215773
EARLY BLOOD STREAM INFECTION AFTER BMT IS ASSOCIATED WITH CYTOKINE DYSREGULATION AND POOR OVERALL SURVIVAL
EHA Learning Center, Kate Markey, 215774
COMPLEMENT-RELATED GENETIC VARIANTS IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY
EHA Learning Center, Eleni Gavriilaki, 215789
MURINE MODELS FOR ESTABLISHING STEROID REFRACTORY GVHD
EHA Learning Center, Tomomi Toubai, 215790
LEPTIN IS ASSOCIATED WITH THE DEGREE OF ANEMIA AND THE ERYTHROPOIETIN LEVELS IN Β THALASSEMIA PATIENTS
EHA Learning Center, Carina Levin, 215806
MUTATION SPECTRUM IN HBB, HBA1 AND HBA2 GENES IN PATIENTS FROM EUROPEAN PART OF RUSSIA
EHA Learning Center, Svetlana Mann, 215807
INTRACRANIAL HEMORRHAGE IN LEUKEMIA PATIENTS: PRELIMINARY RESULTS OF AN ONGOING NESTED CASE CONTROL STUDY
EHA Learning Center, Loes Cornelissen, 215822
QUALITY CONTROL IN CRYOPRESERVED POOLED PLATELETS: 9-YEAR EXPERIENCE IN A TRANSFUSION CENTRE.
EHA Learning Center, Pablo Romero Garcia, 215823
PI3P MODULATES MEGAKARYOCYTE MATURATION AND PROPLATELET PRODUCTION IN VITRO
EHA Learning Center, Ivana Bertović, 215902
NIVOLUMAB TREATMENT DISCONTINUATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY EXPERIENCE
EHA Learning Center, Liudmila Fedorova, 215903
THE OXYGENSCAN: CONTINUOUS MEASUREMENT AND QUANTIFICATION OF SICKLING DURING DE- AND REOXYGENATION TO MONITOR DISEASE SEVERITY AND TREATMENT EFFECT IN SICKLE CELL DISEASE.
EHA Learning Center, Minke Rab, 215918
ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOMES THE NEGATIVE PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN TRANSPLANT ELIGIBLE PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA.
EHA Learning Center, Abhishek Mangaonkar, 215919

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings